

CLAIMS

1. An agent for treating diabetes with sulfonylurea secondary failure which comprises a dipeptidyl peptidase IV inhibitor.

5

2. The agent according to Claim 1 wherein the sulfonylurea secondary failure is ascribable to a sulfonylurea compound.

10

3. The agent according to Claim 1 wherein the sulfonylurea secondary failure is ascribable to a fast-acting insulin secretagogue.

15

4. Use of a dipeptidyl peptidase IV inhibitor for manufacture of an agent for treating diabetes with sulfonylurea secondary failure.

20

5. A method of treating diabetes with sulfonylurea secondary failure in a mammal which comprises administering an effective amount of a dipeptidyl peptidase IV inhibitor to the mammal.

25

6. An insulin secretagogue for diabetic patients with sulfonylurea secondary failure which comprises a dipeptidyl peptidase IV inhibitor.

7. Use of a dipeptidyl peptidase IV inhibitor for manufacture of an insulin secretagogue for diabetic patients with sulfonylurea secondary failure.

5

8. A method of promoting insulin secretion in a diabetic patient with sulfonylurea secondary failure which comprises administering an effective amount of a dipeptidyl peptidase IV inhibitor to the patient.

10